(1)
PolistenaB.; SpandonaroF.; CapraR.; FantacciniS.; SantoniL.; ZimatoreG.; GasperiniC. The Societal Impact of Treatment With Natalizumab of Relapsing–remitting Multiple Sclerosis in Italian Clinical Practice: The Tysabri® PharmacoEconomics (TyPE) Study. GRHTA 2019, 6.